Public Health Vaccines LLC
Public Health Vaccines (PHV) is a privately-held biotechnology company dedicated to developing vaccines for the prevention and control of global Emerging Infectious Diseases. With years of experience in vaccine and medical countermeasure products, PHV's mission is to develop and advance novel vaccines that address significant global public health threats. The company leverages its expertise to deliver potentially life-saving medical countermeasures aligned with the evolving global landscape.
Industries
Nr. of Employees
small (1-50)
Public Health Vaccines LLC
Cambridge, Massachusetts, United States, North America
Products
Marburg virus vaccine candidate (rVSV-based)
A single-dose vaccine candidate against Marburg virus developed on a recombinant VSV-type replicating viral vector platform; preclinical efficacy in primate models and advanced development under a government advanced development contract.
Nipah virus vaccine candidate (rVSV-based)
A live, attenuated single-dose vaccine candidate against Nipah virus using a vesicular stomatitis virus vector; funded to progress through Phase 2 clinical testing under a partnership with a global epidemic preparedness funder.
Sudan ebolavirus (SUDV) vaccine candidate (rVSV-based)
A vaccine candidate targeting Sudan ebolavirus generated on a recombinant VSV-type vector platform; constructed using starting materials from a national public health laboratory and mirroring platform design used for other filovirus vaccines.
Marburg virus vaccine candidate (rVSV-based)
A single-dose vaccine candidate against Marburg virus developed on a recombinant VSV-type replicating viral vector platform; preclinical efficacy in primate models and advanced development under a government advanced development contract.
Nipah virus vaccine candidate (rVSV-based)
A live, attenuated single-dose vaccine candidate against Nipah virus using a vesicular stomatitis virus vector; funded to progress through Phase 2 clinical testing under a partnership with a global epidemic preparedness funder.
Sudan ebolavirus (SUDV) vaccine candidate (rVSV-based)
A vaccine candidate targeting Sudan ebolavirus generated on a recombinant VSV-type vector platform; constructed using starting materials from a national public health laboratory and mirroring platform design used for other filovirus vaccines.
Services
Vaccine research and development
R&D of vaccine candidates against emerging infectious diseases using recombinant viral vector platforms, including preclinical evaluation and preparation for clinical testing.
Advanced development and program management for government-funded projects
Management and execution of advanced development activities under government contracts and partnerships, including coordination with funders and subcontractors.
Vaccine research and development
R&D of vaccine candidates against emerging infectious diseases using recombinant viral vector platforms, including preclinical evaluation and preparation for clinical testing.
Advanced development and program management for government-funded projects
Management and execution of advanced development activities under government contracts and partnerships, including coordination with funders and subcontractors.
Expertise Areas
- Viral-vector vaccine development
- Filovirus and emerging infectious disease vaccines
- Clinical trial management (Phase 1–2)
- Nonclinical/animal model efficacy studies
Key Technologies
- Recombinant vesicular stomatitis virus (rVSV-type) vector platform
- Live attenuated single-dose vaccine design
- Nonhuman primate efficacy models
- cGMP manufacturing and technology transfer